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Abstract The binding of proteins from an immortalised B-cell 
line to a panel of SH3 domains was investigated in vitro. One of 
tht* most prominent SH3 domain binding proteins was a 68 kD 
polypeptide which strongly associated with the SH3 domains of 
c-src, p85a and p47phor and weakly with the SH3 domain of 
PLCy and n-src with undetectable binding to the other SH3 
domains tested. Immunoblotting identified this protein as human 
Sam68. The ability of proline-rich peptides homologous to the 
Sam68 primary sequence to inhibit the binding of Sam68 to SH3 
domains was investigated. Only one peptide inhibited binding of 
Sam68 to the p85a SH3 domain, whereas several peptides 
inhibited binding of Sam68 to c-src SH3 domain, suggesting that 
Sam68 uses different protine-rich motifs to bind to different SH3 
domains. A peptide derived from residues 32-4 of Sam68 which 
fits the class II SH3 domain binding consensus sequence inhibited 
binding of Sam68 to both p85a SH3 domain and c-src SH3 
domain, but with differential potency, suggesting a differential 
affmity of these SH3 domains for this proline-rich motif. 
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I. Introduction 
!t has become clear that intracellular associations are neces- 
sa-y for signal transduction within cells, and in many cases 
this is mediated by the binding of specific SH2 domains to 
defined phosphotyrosine-containing peptide sequences [ 1,2]. 
The interaction of distinct SH2 domains with phosphotyrosyl 
peDtides is determined by the residues immediately carboxy 
terminus to the phosphotyrosine residue, and the binding spe- 
cif cities of over 20 SH2 domains have now been characterised 
[3- 51. Many signalling molecules also contain SH3 domains; 
however, less is known about the biological functions and 
asb.ociations of SH3 domains. The first report of an SH3-bind- 
ing motif described a proline-rich sequence [6], and a number 
of SH3 ligands have now been identified. All SH3 domain 
ligmds to date have a PXXP motif, and these fall into two 
general classes: class I ligands contain an Arg residue N-ter- 
mlnal to the PxxP motif, whereas the Arg residue lies C-ter- 
mlnal to the core motif in Class II ligands. Interestingly, PPII 
he ices are pseudo-symmetrical and Class I and Class II li- 
ga ids have been predicted to fit into the SH3 domain binding 
sit : in two orientations [7-91. SH3 domains are not restricted 
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to signalling molecules, since cytoskeletal proteins such as 
myosin I and a-spectrin also contain these homologies. In 
addition the proteins p40pho”, p67pho” and p47phox, which are 
cytoplasmic components of the phagocyte NADPH oxidase, 
contain SH3 domains, the latter two components each having 
two SH3 domains and one SH3-binding motif, and the cyto- 
plasmic tail of the membrane component of the NADPH 
oxidase, p22phox, also has an SH3-binding motif [lO,ll]. These 
regions are responsible for specific intermolecular interactions 
which regulate the assembly and activation of this enzyme, 
leading to the generation of superoxide. Since these compo- 
nents become detergent insoluble after activation, and are 
regulated by rat, it is possible that they might fit the criteria 
for cytoskeletal SH3 domain-containing proteins. EBV-trans- 
formed B-cells also have an NADPH oxidase identical to that 
found in phagocytes, but also have a number of signalling 
molecules and cytoskeletal proteins common to many cells. 
In an attempt to further investigate the role of SH3 do- 
main-mediated interactions in B-cells we have investigated 
the ability of proteins from an EBV-transformed B-cell line 
to bind to distinct SH3 domains and report here the specific 
interaction of Sam68 with the SH3 domains derived from 
several proteins including c-src, p85a, PLCy and p47ph”“. 
We have also identified sequences on Sam68 responsible for 
these interactions. 
2. Materials and methods 
2.1. Reagents 
The bacterial expression vector pGEX-4T-1 was purchased from 
Pharmacia. Glutathione-agarose beads were obtained from Sigma. 
Synthetic peptides were synthesised by Zinsser Analytic, Maidenhead, 
UK and Alta Bioscience, Birmingham, UK. Rabbit polyclonal anti- 
sera raised against a carboxy terminal epitope of Sam68 (residues 
424443) was purchased from Santa Cruz Biotechnology, Santa 
Cruz, CA. 
2.2. Cell culture 
HL60 and Namalwa cells were cultured in RPM1 1640 and 10% 
heat-inactivated fetal calf serum containing 2 mM L-glutamine at 37°C 
in 5% COz. HL60 cells were differentiated into neutrophilic cells by 
the addition of DMSO to a final concentration of 1.25% for 5 days. 
2.3. Glutathione S-transferase fusion proteins 
DNA sequences encoding the N-terminal SH3 domains of p47phox 
(aa 157-215) and p67 phox (aa 237-398) were amplified by PCR from a 
human neutrophil phage library (Clontech) and cloned into the 
pGEX-4T-1 expression vector. PCR primers corresponding to each 
end of the SH3 domains contained EcoRI and .SalI sites (p47N- 
SH3) or EcoRI and XhoI sites (p67N-SH3) to facilitate cloning. The 
pGEX constructs were sequenced using the Sequenase system (US 
Biochemicals). The remaining pGEX-SH3 constructs have been de- 
scribed previously [11,22]. Constructs were transformed into Escheri- 
chia coli XLl-Blue and expression of GST fusion proteins performed 
as described previously [23]. 
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2.4. GST-SH3 binding assays 
Affinity matrices were prepared by immobilising 25 ug of fusion 
protein on 50 11 of glutathione-agarose beads (Sigma). Differentiated 
HL60 cells and Namalwa cells were pelleted and washed twice in 
phosphate buffered saline. Cell pellets were solubilised in lysis buffer 
(50 mM Tris pH 7.5, 5 mM EGTA, 2% (v/v) Triton X-100, 75 mM 
NaCI, 0.5 mM PMSF) and clarified by centrifugation at 14000 Xg for 
15 min at 4°C. Cell lysates from the equivalent of 5 x lo6 cells for 
silver staining or lo6 cells for Western blotting were mixed with the 
GST-SH3 affinitv matrices for 3 h at 4°C. The beads were then 
washed extensively in wash buffer (50 mM Tris pH 7.5, 0.1% (v/v) 
Triton X-100, 10% (v/v) glycerol). Binding proteins were eluted by 
boiling in SDS-PAGE sample buffer, resolved by SDS-PAGE and 
visualised by immunoblotting with an antibody to Sam68 or by silver 
staining. In addition, binding assays were performed in the presence 
of proline-rich synthetic peptides at concentrations indicated in the 
relevant figure legends. 
3. Results 
Initial experiments were performed to compare the SH3 
A 
GST p47N p47NC PLCy ~85 
M HN HN HN HN HN 
B 
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Fig. 1. (A) In vitro binding of detergent-soluble proteins from Na- 
malwa cells (N) or differentiated HL60 cells (H) to immobilized 
GST-SH3 fusion proteins. Lysates were incubated with glutathione- 
agarose beads bound with GST or GST fusion proteins containing 
the N-terminal SH3 domain of p47pho” (p47N), the tandem SH3 do- 
mains of p47rhox (p47NC), the phospholipase Cy SH3 domain 
(PLQ) or the SH3 domain of the p85a subunit of phosphatidylino- 
sitol 3-kinase (~85). Bound proteins were eluted with SDS-PAGE 
sample buffer, resolved by SDS-PAGE and visualised by silver 
staining. (B) Identification of p68 as Sam68 by Western blotting. 
SH3 domain-binding proteins were purified as described for (A) 
Following SDS-PAGE, proteins were transferred to nitrocellulose 
and probed with an antibody to Sam68 as described in Section 2. 
The arrowhead shows the position of Sam68. 
Fig. 2. In vitro binding of Sam68 to a panel of immobilised SH3 
domains. Triton X-100 lysates of Namalwa cells were bound to 
GST-SH3 domains and Western blotting with anti-Sam68 performed 
as described for Fig. 1. Additional tracks are: LYS, total Triton X- 
100 cell lysate before binding; BEADS, glutathione beads with no 
immobilised fusion GST fusion nrotein: GST. immobilised GST: , 
c-SRC, the SH3 domain of c-src; n-SRC, the SH3 domain of neu- 
ronal (n)-src; FGR, the SH3 domain of c-fgr; p67N, the N-terminal 
SH3 domain of p67phox; p67C, the carboxy-terminal domain of 
p67ph”. The arrowhead shows the position of Sam68. 
domain-binding protein profiles of two haemopoietic cell 
lines: neutrophil-differentiated HL60 cells and Namalwa B- 
cells. Triton X-100 lysates were prepared from these cells 
and the proteins allowed to bind to immobilised SH3 do- 
mains. Fig. 1A shows the SH3 domain-binding protein pro- 
files visualised by silver staining. Whilst there were several 
differences between the binding of HL60 proteins and Namal- 
wa proteins, the most prominent was a 68 kD polypeptide 
from Namalwa cells which strongly associated with the SH3 
domains of p85a and p47 phox and weakly with the SH3 do- 
main of PLCy. This was characterised using a battery of anti- 
bodies against 68 kD proteins, and ~68 was found to cross- 
react with an antibody against Sam68 [18,19]. The identity of 
~68 as Sam68 was confirmed by Western blotting of the SH3- 
binding proteins, showing the SH3-binding profile of Sam68 
was identical to that of ~68 visualised by silver staining (Fig. 
IB). The specificity of Sam68 binding was further investigated 
by studying its association to a larger panel of SH3 domains. 
Western blotting of bound proteins revealed that there was 
intense staining of Sam68 bound to the SH3 domains from 
c-src, p85a, c-fgr and the N-terminal SH3 domain of p47rh”“. 
There was less intense staining to the SH3 domains of n-src 
and PLCy, and binding was undetectable to the other SH3 
domains tested (Fig. 2), indicating that Sam68 from Namalwa 
cells bound to a restricted set of SH3 domains. 
The absence of Sam68 binding from HL60 lysates was in- 
vestigated. Both Namalwa cells and HL60 cells contained 
comparable amounts of Sam68 when total cell lysates were 
blotted and in fact contained higher levels than human fibro- 
blasts (Fig. 3). However, only the Triton X-100 lysate from 
Namalwa cells contained Sam68 (Fig. lB, lanes marked LYS), 
therefore the apparent absence of Sam68 binding in HL60 
lysates was due to the lack of solubility of Sam68 from 
HL60 cells into Triton-containing buffer. The reason for this 
differential extraction is unknown but it is possible that there 
are functional differences between Sam68 from these two cell 
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F g. 3. Detection of Sam68 in haemopoietic cells. Cell pellets were 
SC lubilised into SDS-PAGE sample buffer and the extracted proteins 
subjected to Western blotting with anti-Sam68. p47/CBP, tandem 
PL 7phox SH3 domain binding protein; UHL60, undifferentiated 
HL60 cells; DHL60, differentiated HL60 cells; MRCS, MRC5 hu- 
mm fibroblasts; NAM, Namalwa cells; MOLT4, human T-cells. 
T re arrowhead shows the position of Sam68 
types, related to cell proliferation or other aspects of activa- 
tion such as superoxide production. 
Several proline-rich putative SH3 binding domains were 
identified in Sam68 Six peptides corresponding to these re- 
gr,ms were synthesised (see Table 1) and their ability to block 
the binding of Sam68 to immobilised SH3 domains was ex- 
arnined. At 500 uM only peptide P2 significantly inhibited the 
blnding of Sam68 to p85a, whereas peptides Pl, P2 and P6 
inhibited the binding of Sam68 to c-src SH3 domain (Fig. 4). 
P‘hptide P2 appeared to inhibit the binding of Sam68 to c-src 
greater than to p85rx SH3 domain, and this was confirmed by 
dc)se-response experiments. Whilst the ICss of peptide P2 for 
Sm68 binding to c-src SH3 was < 50 pM, the ICss of peptide 
P ! for Sam68 binding to p85a SH3 was > 400 uM (Fig. 5), 
w’rich suggests that c-src SH3 domain binds to this proline- 
ri<:h motif with greater affinity than p85a SH3 domain. 
4. Discussion 
We have identified a 68 kD SH3 domain-binding protein 
fr rm Namalwa cells as Sam68 [18,19]. The cDNA for Sam68 
w ts originally thought to encode a 62 kD RasGAP-associated 
PI otein (~62); however, recent experiments have confirmed 
that this cDNA does indeed encode the 68 kD Sam68 protein 
and not ~62. The cDNA for p62 has yet to be cloned and is 
unlikely to be related to Sam68 [18]. Sam68 was originally 
identified as a c-src-binding protein in fibroblasts whose asso- 
ciation was upregulated during mitosis [13,14] or oncogenic 
transformation [15]. This association was shown to be depen- 
dent on tyrosine phosphorylation of the carboxy-terminal do- 
main which then directs binding of Sam68 to specific SH2 
domains of several proteins including src, fyn, lyn, RasGAP, 
p85a, and grb2 [13-171. In contrast to SH2 domain binding, 
Sam68 from either asynchronous or mitotic fibroblasts binds 
constitutively to the SH3 domain of c-src [13,14], thus the 
SH3 domain association of Sam68 may be functionally dis- 
tinct from its SH2 domain binding. Whilst Sam68 has homol- 
ogy to heteroribonucleoprotein K (hnRNPK), and can bind 
to RNA in vitro, its function within cells at present is un- 
known [ 12,13,18,19]. Despite earlier reports it does not associ- 
ate with RasGAP [20], and it has now been shown that p62 
and Sam68 are distinct unrelated proteins [14,18]. The results 
presented here demonstrating the binding of Sam68 from 
asynchronous transformed B-cells to distinct SH3 domains 
are consistent with previous findings in fibroblasts, and extend 
previous studies to show constitutive binding to a number of 
SH3 domains. Furthermore, Sam68 from growing B-cells had 
different extraction properties from nonproliferating differen- 
tiated HL60 cells. Haemopoietic cells appeared to express 
more Sam68 than fibroblasts and the reason for this is un- 
known. Namalwa Sam68 bound with apparently high effi- 
ciency to the SH3 domains of c-src, p85a and fgr, and bound 
with lower apparent efficiency to the SH3 domain of PLCy. 
This is in broad agreement with a previous study [17], with the 
exception that no binding of Sam68 to the SH3 domain of fgr 
T. ble 1 
SI mmary of the inhibition of binding of Sam68 to SH3 domains by proline-rich peptides derived from human Sam68 sequence 
6 ptide Sequence (Res) Inhibition of: 
p85SH3/Sam68 c-srcSH3/Sam68 
P, ASPATQPPPLLPPSA (57-71) +++ 
P: QTPSRQPPLPHRS (3244) + ++ 
P.’ GGPAPTPLLPPSA (79991) _ 
Pk RIPLPPPPAPET (354365) _ _ 
P: AAPPPPPVPRG (2933303) _ _ 
PC TRGVPPPPTVRGAPA (33c344) _ + 
143 
SH3 c-------p85u - 7c-src----_( 
PEP - 12 3 4 5 6 -1 2 3 456 
Fig. 4. Inhibition of Sam68 binding to p85cx or c-src SH3 domains 
by proline-rich peptides derived from Sam68 sequence. Namalwa 
cell lysates were incubated with ~85112 or c-src SH3 domains in the 
presence of 500 FM Sam68-derived peptides as described in Table 1 
and Sam68 binding detected by Western blotting. The arrowhead 
shows the position of Sam68. 
_ __._.. _-._.._ 
Fig. 5. Dose response of inhibition of Sam68 binding to p85a or 
c-src SH3 domains in the presence of increasing concentrations of 
peptide P2. See Fig. 4 for details of methodology. 
was found. Others have also reported binding of a p62-related 
protein to PLCy [16,21]. In addition we have shown that 
Sam68 associates with the N-terminal SH3 domain of 
p47Ph”“. The significance of this is unknown; however, 
p47 phox is a component of the phagocyte NADPH oxidase 
complex, which is also functional in Namalwa cells (P. Ben- 
nett and S. Kellie, unpublished). 
The use of proline-rich peptides based on the Sam68 se- 
quence has allowed partial elucidation of the SH3 domain 
binding sites. Namalwa Sam68 binding to p85a SH3 domain 
could be inhibited only by peptide P2, whereas binding of 
Sam68 to c-src SH3 domain was inhibited by peptides Pl, 
P2 and P6, suggesting that Sam68 uses only residues 3244 
to bind to p85cr SH3 but uses this motif plus at least two 
others for binding to c-src SH3. In agreement with our results 
that peptide P6 encompassing residues 330-344 inhibits 
Sam68 binding to c-src SH3 is the report that Sam68 deleted 
in this region is partially defective in c-src SH3 binding [16]. 
Peptide P2, which inhibited binding to both c-src and p85a 
SH3 domains contains the sequence ..QPPLPHR.., which fits 
exactly the XPXLNPXR sequence of class II SH3-binding 
motifs, suggesting that at least one of the Sam68 motifs might 
bind both SH3 domains in reverse orientation [7-91. A recent 
report has described a peptide homologous to our P4 which 
partially inhibits Sam68 binding to c-src SH3 domain and a 
longer peptide with homology to PS which blocked binding of 
Sam68 to c-src SH3 [17]; however, these differences may be 
due to different experimental techniques since these workers 
used in vitro translated Sam68 for binding studies whereas we 
have used Sam68 from cell lysates, which might be post-trans- 
lationally modified or differently folded to confer different 
binding characteristics, for example by masking specific pro- 
line-rich motifs. However, we unequivocally demonstrate in 
this report that a peptide comprising residues 3244 strongly 
inhibits the association of Sam68 with c-src SH3 domain. 
Whilst a similar peptide was reported to be ineffective [17], 
P. J. Finan et al.IFEBS Letters 389 (1996) 141-144 
in that report the peptide tested was truncated before the 
arginine residue, so destroying the class II binding motif. 
This same sequence is mutated to ..PSPLPHR.. in murine 
Sam68, again destroying the class II binding motif, and this 
might explain the failure to detect this as a functional binding 
motif in murine Sam68 [16]. In summary, this paper describes 
an interaction between Sam68 from B-cells and specific SH3 
domains, including a component of the NADPH oxidase, and 
further defines a putative novel binding site for the association 
of Sam68 with the SH3 domains of c-src and ~8%. 
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